News
CING
4.830
-2.23%
-0.110
Weekly Report: what happened at CING last week (0615-0619)?
Weekly Report · 1d ago
Cingulate Gains Key U.S. Patent for Lead ADHD Drug
TipRanks · 06/16 12:46
Cingulate issues patent by USPTO for CTx-1301
TipRanks · 06/16 12:17
Cingulate wins first US patent for ADHD drug CTx-1301, exclusivity to December 2042
PUBT · 06/16 12:02
Weekly Report: what happened at CING last week (0608-0612)?
Weekly Report · 06/15 10:32
Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 06/09 13:39
Insider Makes Bold Move With Major Cingulate Inc. Stock Purchase
TipRanks · 06/09 02:12
Cingulate director Jeff Hargroves acquires 97,276 common shares for $490,271.04
PUBT · 06/08 23:02
Cingulate files Form 3 initial beneficial ownership statement for director Jeff Hargroves
PUBT · 06/08 23:00
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 06/08 13:52
Weekly Report: what happened at CING last week (0601-0605)?
Weekly Report · 06/08 10:27
Cingulate Is Maintained at Buy by Ascendiant Capital
Dow Jones · 06/08 09:56
Cingulate Price Target Cut to $52.00/Share From $55.00 by Ascendiant Capital
Dow Jones · 06/08 09:56
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $52
Benzinga · 06/08 09:46
Roth sees ‘major silver lining’ in Cingulate complete response letter
TipRanks · 06/04 10:50
Top Biotech Gainers: ABVX, CING, DRTS, MMED...
NASDAQ · 06/04 02:38
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 06/03 17:06
Naz Rahman Reiterates Buy on Cingulate, Maintains 12‑Month Price Target at $8 Following FDA Manufacturing-Only Setback
TipRanks · 06/03 15:25
Largest borrow rate increases among liquid names
TipRanks · 06/03 15:18
Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL
NASDAQ · 06/03 02:11
More
Webull provides a variety of real-time CING stock news. You can receive the latest news about Cingulate Inc through multiple platforms. This information may help you make smarter investment decisions.
About CING
Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.